Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
05 Setembro 2023 - 8:30AM
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage
biotechnology company discovering and developing tumor-activated
immuno-oncology therapies for people living with cancer, today
announced that René Russo, Pharm.D., chief executive officer, will
participate in a fireside chat at the Morgan Stanley 21st Annual
Global Healthcare Conference on Monday, September 11, 2023, at 2:55
pm EST.
A live webcast can be accessed under “Events &
Presentations” in the Investors & Media section of the Xilio
Therapeutics website at https://ir.xiliotx.com/. A replay of the
webcast will be archived on the website for 30 days following the
presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company
discovering and developing tumor-activated immuno-oncology (I-O)
therapies with the goal of significantly improving outcomes for
people living with cancer without the systemic side effects of
current I-O treatments. The company is using its proprietary
geographically precise solutions (GPS) platform to build a pipeline
of novel, tumor-activated molecules, including antibodies,
cytokines and other biologics, which are designed to optimize their
therapeutic index and localize anti-tumor activity within the tumor
microenvironment. Xilio is currently advancing multiple programs
for tumor-activated I-O treatments in clinical development, as well
as programs in preclinical development. Learn more by visiting
www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics,
Inc.).
This press release contains hyperlinks to
information that is not deemed to be incorporated by reference in
this press release.
For Investor and Media Inquiries: Julissa
VianaVice President, Head of Investor Relations and Corporate
Communicationsinvestors@xiliotx.com
Melissa ForstArgot PartnersXilio@argotpartners.com
Xilio Therapeutics (NASDAQ:XLO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Xilio Therapeutics (NASDAQ:XLO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024